Korea Investment CORP increased its stake in shares of Core Laboratories N.V. (NYSE:CLB) by 22.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 53,600 shares of the oil and gas company’s stock after buying an additional 10,000 shares during the period. Korea Investment CORP owned about 0.12% of Core Laboratories N.V. worth $5,428,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. Telemus Capital LLC raised its stake in shares of Core Laboratories N.V. by 1.0% in the second quarter. Telemus Capital LLC now owns 25,608 shares of the oil and gas company’s stock valued at $2,593,000 after buying an additional 244 shares during the period. Sei Investments Co. raised its stake in shares of Core Laboratories N.V. by 59.0% in the second quarter. Sei Investments Co. now owns 665,817 shares of the oil and gas company’s stock valued at $67,426,000 after buying an additional 247,042 shares during the period. Garde Capital Inc. bought a new stake in shares of Core Laboratories N.V. during the second quarter valued at about $437,000. Bbva Compass Bancshares Inc. raised its stake in shares of Core Laboratories N.V. by 8.0% in the second quarter. Bbva Compass Bancshares Inc. now owns 10,551 shares of the oil and gas company’s stock valued at $1,068,000 after buying an additional 780 shares during the period. Finally, Janney Montgomery Scott LLC raised its stake in shares of Core Laboratories N.V. by 2.7% in the second quarter. Janney Montgomery Scott LLC now owns 11,676 shares of the oil and gas company’s stock valued at $1,182,000 after buying an additional 309 shares during the period.

Shares of Core Laboratories N.V. (NYSE:CLB) opened at 92.92 on Friday. The company has a market capitalization of $4.10 billion, a price-to-earnings ratio of 57.01 and a beta of 1.60. Core Laboratories N.V. has a 1-year low of $92.81 and a 1-year high of $125.83. The stock has a 50 day moving average of $101.46 and a 200-day moving average of $108.84.

Core Laboratories N.V. (NYSE:CLB) last issued its earnings results on Monday, July 24th. The oil and gas company reported $0.52 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.51 by $0.01. Core Laboratories N.V. had a return on equity of 49.29% and a net margin of 11.80%. The business had revenue of $163.90 million during the quarter, compared to analyst estimates of $168.23 million. During the same quarter in the previous year, the firm earned $0.35 EPS. Core Laboratories N.V.’s revenue was up 10.7% on a year-over-year basis. Analysts forecast that Core Laboratories N.V. will post $2.09 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 14th. Shareholders of record on Monday, July 17th will be given a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 2.37%. The ex-dividend date is Thursday, July 13th. Core Laboratories N.V.’s dividend payout ratio (DPR) is 134.15%.

TRADEMARK VIOLATION WARNING: This news story was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of United States and international trademark & copyright legislation. The legal version of this news story can be viewed at https://theolympiareport.com/2017/08/12/korea-investment-corp-raises-position-in-core-laboratories-n-v-nyseclb.html.

Several brokerages recently issued reports on CLB. Morgan Stanley decreased their price target on shares of Core Laboratories N.V. from $130.00 to $125.00 and set an “overweight” rating on the stock in a report on Monday, August 7th. ValuEngine raised shares of Core Laboratories N.V. from a “sell” rating to a “hold” rating in a report on Friday, August 4th. BidaskClub lowered shares of Core Laboratories N.V. from a “hold” rating to a “sell” rating in a report on Monday, July 31st. Citigroup Inc. reduced their target price on shares of Core Laboratories N.V. from $102.00 to $100.00 and set a “neutral” rating on the stock in a report on Wednesday, July 26th. Finally, UBS AG reissued a “neutral” rating and set a $110.00 target price (down from $125.00) on shares of Core Laboratories N.V. in a report on Wednesday, July 26th. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $117.17.

About Core Laboratories N.V.

Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.

Want to see what other hedge funds are holding CLB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Core Laboratories N.V. (NYSE:CLB).

Institutional Ownership by Quarter for Core Laboratories N.V. (NYSE:CLB)

Receive News & Ratings for Core Laboratories N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.